<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531517</url>
  </required_header>
  <id_info>
    <org_study_id>Pedyphar2012</org_study_id>
    <nct_id>NCT01531517</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy of PedyPhar速 Ointment on the Diabetic Foot Ulcers</brief_title>
  <acronym>PED111</acronym>
  <official_title>Study of the Efficacy of Topical Application of Royal Jelly and Panthenol (PedyPhar速 Ointment) on the Diabetic Foot Ulcers, An Open Label, Randomized, Non-placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Egyptian Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Egyptian Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial Phase III-b&#xD;
&#xD;
      Study Sponsor:&#xD;
&#xD;
      European Egyptian Pharmaceutical Industries&#xD;
&#xD;
      Sample Size:&#xD;
&#xD;
      120 patients (60 per arm)&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      Patients with Diabetic foot ulcer of any stage after proper surgical treatment - if needed.&#xD;
      Those patients will be recruited from patients attending the Diabetic foot Center at Faculty&#xD;
      of Medicine - Alexandria University and the outpatient clinic at Faculty of Medicine, Cairo&#xD;
      University.&#xD;
&#xD;
      Recruitment Period: 9 months&#xD;
&#xD;
      Dose application: thick layer of 2-3 mm applied to the dressing then dressing applied to the&#xD;
      ulcer.&#xD;
&#xD;
      Endpoints: Complete healing of the ulcer OR 5 months of application of the ointment whichever&#xD;
      comes first&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:&#xD;
&#xD;
      This is an open label randomized non-placebo study in which 120 subjects will be randomly&#xD;
      allocated to treatment with PedyPhar ointment or Panthenol ointment for their diabetic foot&#xD;
      ulcer. Treatment with the ointment will be preceded by appropriate surgical treatment to&#xD;
      remove necrotic tissue as indicated by a surgeon for foot ulcer Wagner stages 3-5. Also,&#xD;
      diabetic status will be controlled as part of the study. Ointment in either arm will be&#xD;
      applied to the ulcer for a maximum of 5 months or till complete healing whichever happens&#xD;
      first.&#xD;
&#xD;
      Patients will visit study center every 2 weeks where assessment of the ulcer will be done and&#xD;
      patient will be given the ointment for the dressing enough for 2 weeks.&#xD;
&#xD;
      Blood flow in the affected leg will be assessed besides kidney functions complete blood&#xD;
      picture besides kidney functions. Diabetic status will be monitored every months and&#xD;
      glycosylated hemoglobin will be done every 3 months&#xD;
&#xD;
      Study Duration: 12 months&#xD;
&#xD;
      Study Agent/Intervention Description: PEDYPHAR速 is a new patented local ointment composed of&#xD;
      natural (Royal Jelly) and (Dexpanthenol) in an innovated, enriched alkaline ointment base.&#xD;
&#xD;
      Dose application: thick layer of 2-3 mm applied to the dressing then dressing applied to the&#xD;
      ulcer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    inability to recruit patients&#xD;
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing of the Ulcer</measure>
    <time_frame>within 5 months or complete healing whichever comes first</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of infection in the ulcer site</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local reaction that may be due to study drug</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Pedyphar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ointment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panthenol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ointment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Royal Jelly and Panthenol (PedyPhar速 Ointment)</intervention_name>
    <description>the following will be done to each patient depending on the number of the visit:&#xD;
Assessment of the patient for inclusion/exclusion criteria&#xD;
Informed consent process&#xD;
Medical history of the patient&#xD;
Blood withdrawn for investigation&#xD;
Drainage of the ulcer if there is a collection&#xD;
Revascularization as needed and indicated by APSV done at visit 0.&#xD;
Swab from the ulcer for culture and micro-organism count: on detailed visits only.&#xD;
Debridement as needed.&#xD;
Dressing:&#xD;
Inspection and assessment of the ulcer&#xD;
Irrigation using 500 ml of saline or as required.&#xD;
Drying of the ulcer (leave to dry)&#xD;
Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer&#xD;
Fix the dressing to the ulcer</description>
    <arm_group_label>Pedyphar</arm_group_label>
    <other_name>Pedyphar</other_name>
    <other_name>Panthenol</other_name>
    <other_name>Royal Jelly</other_name>
    <other_name>Ointment</other_name>
    <other_name>Diabetic Foot Ulcer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panthenol Ointment</intervention_name>
    <description>the following will be done to each patient depending on the number of the visit:&#xD;
Assessment of the patient for inclusion/exclusion criteria&#xD;
Informed consent process&#xD;
Medical history of the patient&#xD;
Blood withdrawn for investigation&#xD;
Drainage of the ulcer if there is a collection&#xD;
Revascularization as needed and indicated by APSV done at visit 0.&#xD;
Swab from the ulcer for culture and micro-organism count: on detailed visits only.&#xD;
Debridement as needed.&#xD;
Dressing:&#xD;
Inspection and assessment of the ulcer&#xD;
Irrigation using 500 ml of saline or as required.&#xD;
Drying of the ulcer (leave to dry)&#xD;
Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer&#xD;
Fix the dressing to the ulcer</description>
    <arm_group_label>Panthenol</arm_group_label>
    <other_name>Panthenol</other_name>
    <other_name>Ointment</other_name>
    <other_name>Diabetic foot Ulcer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult diabetic foot syndrome subjects over 18 years of age of any sex&#xD;
&#xD;
          -  All stages of diabetic foot syndrome including Wagner stage 5 - Mid-foot gangrene only&#xD;
             after appropriate surgical treatment.&#xD;
&#xD;
          -  Patients suffering from type 1 or type 2 diabetes mellitus with diabetic foot&#xD;
             syndrome.&#xD;
&#xD;
          -  Stable metabolic and pharmacological control at recruitment and during the trial&#xD;
             period.&#xD;
&#xD;
          -  Adequate perfusion of lower limb as measured by HHD and confirmed by APSV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-diabetic foot ulceration (traumatic, thermal ulceration etc)&#xD;
&#xD;
          -  Diabetic foot syndrome graded 5 on Wagner's scale - hind foot gangrene only.&#xD;
&#xD;
          -  Any pathological state or disease which can affect the development and outcomes of&#xD;
             diabetic foot syndrome such as liver cell failure and renal failure&#xD;
&#xD;
          -  Severe limb ischemia (by clinical assessment and HHD) unless re-vascularized.&#xD;
&#xD;
          -  Presence of slough or sequestrum unless debrided.&#xD;
&#xD;
          -  Hemoglobin less than 8 g/dl unless corrected.&#xD;
&#xD;
          -  Those receiving NSAIDs, steroids or anti-mitotic drugs.&#xD;
&#xD;
          -  Septicemia patients requiring urgent amputation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir H Assaad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hesham M Abdel Samad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alexandria University Hospitals</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pedyphar</keyword>
  <keyword>Ointment</keyword>
  <keyword>Healing</keyword>
  <keyword>Diabetic</keyword>
  <keyword>Foot Ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantothenic Acid</mesh_term>
    <mesh_term>Propolis</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

